Professor Fred Saad, MD, FRCS, Professor, and Chairman of Urology and Director of Genitourinary Oncology at the University of Montreal Hospital Center. In this video, he speaks about the ASCO GU 2022 Abstract – PROpel Phase III trial of Lynparza (olaparib) in combination with standard-of-care abiraterone.
Explanation in detail:
PROpel is a phase III trial comparing the efficacy, safety, and tolerability of olaparib with placebo when given in combination with abiraterone to patients with metastatic castration-resistant prostate cancer (mCRPC) who have not previously received chemotherapy or novel hormonal agents (NHAs) (first-line setting).
In PROpel, about 720 patients were to be randomized in a 1:1 ratio to receive either olaparib and abiraterone or placebo and abiraterone treatment. Enrollment was completed, with a total of 796 patients being assigned to the study. Following worldwide enrolment, the China cohort will randomize around 108 more patients in a 1:1 ratio at sites throughout China.
Patients will receive olaparib 300 mg twice daily + abiraterone 1000 mg once daily or placebo twice daily + abiraterone 1000 mg once daily as an oral therapy. Prednisone or prednisolone 5 mg twice daily will be given to patients in both treatment groups.